GlassScriptPhysician profile
Anuradha Kapur
NPI 1023082781
$1,945.20
in general payments reported to CMS, 2019-2025
19 companies · $227 in 2025
The $227 reported for 2025 was more than what 78% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $34.00 · 2021: $413 · 2022: $244 · 2023: $294 · 2024: $552 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $368.44 | 2021-2025 | Wainua |
| Pfizer INC. | $355.37 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $273.25 | 2021-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $136.02 | 2024 | Terlivaz |
| Glaxosmithkline, LLC. | $124.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $109.64 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $109.36 | 2019-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $79.58 | 2021-2024 | |
| Csl Behring | $78.89 | 2021-2023 | Kcentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.16 | 2019-2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $47.16 | 2023-2024 | Rebyota |
| Alnylam Pharmaceuticals INC. | $38.35 | 2025 | |
| Astellas Pharma US INC | $34.50 | 2024 | Cresemba |
| Abbvie INC. | $30.96 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $28.19 | 2022-2023 | Uptravi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.07 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2025 | Austedo Xr |
| Gilead Sciences, INC. | $14.69 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuradha Kapur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.